Transgene SA
Company Profile
Business description
Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.
Contact
400, Boulevard Gonthier d’Andernach
Parc d’Innovation
Illkirch-Graffenstaden
Strasbourg67400
FRAT: +33 388279100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
166
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,456.20 | 90.50 | 1.08% |
| CAC 40 | 7,770.48 | 176.61 | 2.33% |
| DAX 40 | 23,086.65 | 589.67 | 2.62% |
| Dow JONES (US) | 41,317.43 | 564.47 | 1.39% |
| FTSE 100 | 8,596.35 | 99.55 | 1.17% |
| HKSE | 22,504.68 | 385.27 | 1.74% |
| NASDAQ | 17,977.73 | 266.99 | 1.51% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,327.89 | 179.29 | 1.48% |
| S&P 500 | 5,686.67 | 82.53 | 1.47% |
| S&P/ASX 200 | 8,238.00 | 92.40 | 1.13% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |